AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01951716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Graded Glucose Infusion with xenin-25 alone
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes.
Study NCT01951716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Graded Glucose Infusion with GIP plus xenin-25
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP plus xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes.
Study NCT01951716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meal Tolerance Test with Placebo
Description: At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes.
Study NCT01951716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meal Tolerance Test with xenin-25
Description: At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes.
Study NCT03423069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet low in FODMAPs
Description: A strict restriction of all high FODMAP foods for the time of observation. All these foods will be identified by appropriate nutritional visits and alternatives will be suggested to ensure the diet is nutritionally adequate.
Study NCT03423069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Specific dietary advice for IBS
Description: Dietary recommendations such as limitation of alcohol, spicy food and fatty foods, caffeine, carbonated drinks; avoidance of chewing gums and sweeteners containing polyols; small and frequent meals; avoidance of stressful conditions and eating slowly.
Study NCT05720403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates group
Description: Pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Microsoft Teams program will be used to implement the online practice method. The individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes of cool-down and stretching exercises. The exercises will be performed in ten repetitions. The same exercises will be applied in online pilates and face-to-face pilates training.
Study NCT03094156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 capsule of placebo \[to be taken orally, with 240 mL of potable water\]
Study NCT03094156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: 1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]
Study NCT03094156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 250
Description: Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]
Study NCT03094156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comtan®
Description: Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13™
Description: Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose given via IM injection.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq™
Description: RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™
Description: RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentacel™
Description: Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel™
Description: Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RECOMBIVAX HB™
Description: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RECOMBIVAX HB™
Description: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HIBERIX™
Description: HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIBERIX™
Description: HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R™ II
Description: M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R™ II
Description: M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.
Study NCT02734134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-stage exchange joint replacement surgery
Study NCT02734134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage exchange joint replacement surgery
Study NCT00577876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trimix Injection with Doppler Ultrasound
Description: In case a large APA was identified, it will be dissected following the usual technique. Upon completion of the dissection, patients will have intracavernosal injection of 10 units (0.1 ml) of a Trimix administered (PGE1 10 mcg/ml, papaverine hydrochloride 30 mg/mL and phentolamine mesylate 1mg/mL.~Once the patient achieves a pharmacologic erection, the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion.
Study NCT01157767 — intervention group
Intervention type: OTHER
Intervention: standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.
Description: Module I is a group of arm movements. It consists of stretching exercises coordinated with breathing exercises to restore their physical mobility, range of motion and flexibility of shoulders. Module I is to be performed daily. In Module II the exercises are a series of copyrighted, sequential movements designed to put the body in proper alignment. It is a special series of muscle movements to help establish better body alignment, as well as increased strength and flexibility of one's arms, legs, and spine, each exercise is 4 repetitions. Module III is the walking and the resistance weight training program. The walking program is whole body exercise, multi-joint, weight-bearing, low impact and for beginners to advanced.
Study NCT05439382 — intervention group
Intervention type: PROCEDURE
Intervention: Gingival recession regenerative surgery
Description: Bilaminar technique was performed by the same trained operator, opening a primary flap in correspondence of the recession site. Tissue was harvested from palatal donor site and grafted beneath the primary flap
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX™
Description: VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.
Study NCT03620162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX™
Description: VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.
Study NCT03528941 — intervention group
Intervention type: DRUG
Intervention: Lamivudine
Description: Patients who received lamivudine to prevent hepatitis B
Study NCT03528941 — intervention group
Intervention type: OTHER
Intervention: No prophylaxis
Description: Patients who did not receive any prophylaxis to prevent hepatitis B
Study NCT02411643 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: topical calcipotriene 0.005% ointment
Description: Affected area will be treated twice daily for 3 months
Study NCT02515474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: After removing the gallbladder, Laparoscopic common bile duct exploration (LCBDE) was performed by one fulltime attending in laparoscopy in a routine fashion. Access from the opening of the anterior wall of common bile duct or from the dilated cystic duct was acceptable, removed stone(s) and irrigated the duct followed by choledochoscope detection simultaneously. Cholangiograms were also can be a alternative method to obtain stone clearance. If needed, all fluoroscopy was performed by the principal author in the presence of and concurrence with the ERCP endoscopist. Once the LCBDE was completed, the incision of the bile duct was sewed intermittently by absorbed threads, or ligated cystic duct. T-tube was acceptable if needed.
Study NCT02515474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Initially endoscopic retrograde cholangiopancreatography (ERCP) was performed by a fulltime attending and concurrence of the principal author in endoscopy. Patients randomized to ERCP+ LC group were scheduled to undergo the endoscopic procedure using fluoroscopy in the endoscopy center under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Gastric intestinal atony during ERCP was routinely achieved using scopolamine butylbromide injection. Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be choose accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
Study NCT02844595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard cognitive-behavioural smoking cessation treatment
Description: Standard cognitive-behavioural smoking cessation treatment is an effective treatment for tobacco dependence. The treatment elements are: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem solving training, change tobacco related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks.
Study NCT02844595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard cognitive-behavioural smoking cessation treatment and behavioural activation
Description: Behavioural activation will be applied along with standard cognitive-behavioural smoking cessation treatment. The treatment elements are: those present in the standard cognitive-behavioural smoking cessation treatment, plus analysis of the relationship between behaviour and mood, identification of situations and behaviours that decrease mood, identifying avoidance behaviours, and identifying thoughts of rumination and worry, self-report of pleasant daily activities, pleasant activity scheduling to increase engagement in rewarding activities, and to reduce patterns of behavioural avoidance.~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks.
Study NCT06094465 — intervention group
Intervention type: OTHER
Intervention: Different phase of the learning curve of RPD
Description: Different phases of the learning curve of RPD (learning phase or proficiency phase)
Study NCT01940848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STW5 (Iberogast, BAY98-7411)
Description: Applied orally over 28 days, 20 drops STW 5 three times daily
Study NCT01940848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Applied orally over 28 days, 20 drops placebo three times daily
Study NCT00405769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: red yeast rice
Description: 600 mg 3 caps bid
Study NCT00405769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 caps bid
Study NCT03601676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integration of electronic clinical decision support
Description: Integration of an electronic clinical decision support system into the emergency department patient care workflow to assist with site-of-care decision-making for emergency department patients with acute pulmonary embolism.
Study NCT03612219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate tablet
Description: Adjuvant treatment by apatinib mesylate tablet to local advanced nasopharyngeal carcinoma after IMRT with concurrent chemotherapy.the dose of apatinib mesylate tablet was 250 mg,orally,qd,28 days for an observation period,six cycles.
Study NCT03612219 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: Intensity-modulated radiation therapy (IMRT):GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.
Study NCT03612219 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: Intensity-modulated radiation therapy (IMRT):GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.
Study NCT03612219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Concurrent chemotherapy: patients received intravenous cisplatin 80mg/m2(D1-3), 3-week chemotherapy for 3 cycles.
Study NCT03612219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent chemotherapy: patients received intravenous cisplatin 80mg/m2(D1-3), 3-week chemotherapy for 3 cycles.
Study NCT04287348 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Brolucizumab 6 mg solution for intravitreal injection
Description: All consenting, enrolled patients (irrespectively of maximum recurrence-free interval under aflibercept pretreatment) will receive an intravitreal injection of brolucizumab 6 mg at baseline (week 0), at week 4 and each of the following treat and extend visits. At each visit all patients will undergo an OCT assessment. For all patients extension of treatment intervals is only possible 2-week-stepwise, e.g. 4, 6, 8 weeks etc.
Study NCT01610518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oat beta-glucan
Description: 4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
Study NCT01610518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control without beta-glucan. Form (volume) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
Study NCT01369433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib + paclitaxel
Description: Subjects will continue to receive 0.5 mg, 1.0 mg, or 1.5 mg of tivozanib once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment. On days when paclitaxel and tivozanib (AV-951) are co-administered, tivozanib will be administered immediately following the end of the paclitaxel infusion. All subjects will continue to receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off.
Study NCT01369433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib + temsirolimus
Description: Subjects will receive 0.5 mg, 1.0 mg or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks, followed by 1 week off. On days when tivozanib (AV-951) and temsirolimus are co-administered, tivozanib (AV-951) will be administered immediately following temsirolimus infusion. Subjects will receive 15 mg or 25 mg temsirolimus IV once weekly.
Study NCT01369433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
Study NCT01369433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib (AV-951)
Description: Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
Study NCT01369433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib + capecitabine
Description: Subjects will receive 1.5 mg of tivozanib once daily for 2 weeks beginning on Day 1, followed by 1 week off. Subjects will receive Capecitabine (Xeloda®) 825 mg/m2 or 1000 mg/m² or 1250 mg/m² oral twice daily. Subjects will receive capecitabine twice daily for 2 weeks beginning on Day 1, followed by 1 week off.
Study NCT01369433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivo
Description: Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment.
Study NCT03170310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
Study NCT00822471 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Self-Management Education
Description: DSME intervention consisting of two interactive 2-1/2 hour classes taught by a diabetes educator focusing on the ABCs of diabetes and training in how to talk to your doctor.
Study NCT01981083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg albumin-based protein supplement
Study NCT01981083 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Renal-specific oral supplement
Study NCT02347618 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative SBRT
Description: This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
Study NCT00487188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: 90 mg subcutaneous injection twice a day
Study NCT00487188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral treatment (HAART)
Description: An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
Study NCT00487188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Highly active antiretroviral treatment (HAART)
Description: An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
Study NCT04561791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tethered Capsule Endomicroscopy
Description: Participants will be asked to swallow the TCE device. Participants may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE device is past the pharynx. The TCE device will be advanced until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.